Novel Challenges and Therapeutic Options for Pulmonary Embolism and Deep Vein Thrombosis

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (1 October 2023) | Viewed by 1543

Special Issue Editors

Division of Cardiology, Department of Medicine, San Giovanni Bosco Hospital, ASL Città di Torino, 10100 Turin, Italy
Interests: pulmonary embolism; coronary artery disease; ACS; cardiogenic shock; left atrial appendage closure
Division of Cardiology, Department of Medicine, San Giovanni Bosco Hospital, ASL Città di Torino, 10100 Turin, Italy
Interests: pulmonary embolism; coronary artery disease; ACS; cardiogenic shock; intracoronary imaging; interventional cardiology

Special Issue Information

Dear Colleagues,

Venous thromboembolism, clinically presenting as deep vein thrombosis or pulmonary embolism, is the third most frequent acute cardiovascular syndrome.

In this clinical setting, the effects of partial or total occlusion of the pulmonary vascular bed could lead to very different clinical presentations and syndromes, ranging from cardiogenic shock needing hemodynamic support and reperfusion to respiratory failure and chronic pulmonary hypertension. One of the most challenging parts of venous thromboembolism management is the selection of the appropriate treatment according to the risk of the patient. Prediction of the recurrence of future events is still difficult in this scenario. In this regard, a comprehensive evaluation by a pulmonary embolism response team (PERT) is frequently needed to offer a personalized approach.

The aim of this issue is to evaluate the role of new options both medical or interventional for the treatment of pulmonary embolism or deep vein thrombosis as well as new tools for risk stratification such as machine learning or artificial intelligence.

Dr. Giacomo Boccuzzi
Dr. Luca Franchin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary embolism
  • deep vein thrombosis
  • transcatheter thrombectomy
  • risk stratification
  • machine learning
  • chronic thromboembolic pulmonary hypertension

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 478 KiB  
Article
Exploring the Clinical Efficacy of Venous Thromboembolism Management in Saudi Arabian Hospitals: An Insight into Patient Outcomes
by Ebtisam Bakhsh, Mostafa Shaban, Sarah Al Subaie, May Al Moshary and Mohammed AlSheef
J. Pers. Med. 2023, 13(4), 612; https://doi.org/10.3390/jpm13040612 - 31 Mar 2023
Cited by 4 | Viewed by 1272
Abstract
Venous thromboembolism (VTE) is a common condition that can recur, leading to multiple therapeutic strategies to prevent it. The aim of this study was to explore the clinical efficacy of VTE management in Saudi Arabian hospitals and to gain insights into patient outcomes. [...] Read more.
Venous thromboembolism (VTE) is a common condition that can recur, leading to multiple therapeutic strategies to prevent it. The aim of this study was to explore the clinical efficacy of VTE management in Saudi Arabian hospitals and to gain insights into patient outcomes. A retrospective single-center study was conducted that retrieved the data of all patients with VTE registered from January 2015 to December 2017. Patients of all age groups were included if they attended the thrombosis clinic at KFMC during the data collection period. The study analyzed the various therapeutic strategies used for VTE and their effect on patient outcomes. The results showed that 14.6% of the patients had provoked VTE, with a higher incidence among females and younger patients. The most commonly prescribed treatment was combination therapy, followed by warfarin, oral anticoagulants, and factor Xa inhibitor. Despite being prescribed treatment, 74.9% of the patients experienced recurrence of VTE. There was no associated risk factor for recurrence in 79.9% of the patients. Thrombolytic therapy and catheter-directed thrombolysis were found to be associated with a lower risk of VTE recurrence, while anticoagulation therapy, including oral anticoagulants, was associated with a higher risk. Vitamin K antagonist (warfarin) and factor Xa inhibitor (rivaroxaban) had a significant positive association with VTE recurrence, while the use of a direct thrombin inhibitor (dabigatran) showed a lower risk, but it was not statistically significant. The results of the study highlight the need for further research to determine the most effective therapeutic strategy for VTE management in Saudi Arabian hospitals. The findings also suggest that anticoagulation therapy, including oral anticoagulants, may increase the risk of VTE recurrence, while thrombolytic therapy and catheter-directed thrombolysis may lower the risk. Full article
Show Figures

Figure 1

Back to TopTop